T-Cell Therapies for EBV-Associated Malignancies
At present, CTL are being used only in patients with advanced relapsed malignancies. As their safety and efficacy becomes better established we may expect their introduction earlier in the course of therapy where they may reduce the short- and long-term toxicities of standard radio- and chemotherapies. Further understanding of the ways in which immune evasion strategies can be counteracted in Hodgkin’s disease may also be applied to the many other human tumors that are potentially immunogenic and use similar immune evasion strategies.
KeywordsLymphoblastoid Cell Line Latent Membrane Protein Immune Evasion Strategy Latent Membrane Protein Expression Virus Latent Membrane Protein
Unable to display preview. Download preview PDF.
- Rickinson AB (1994) EBV infection and EBV-associated tumors. In: Minson AC, Neil JC, McRae MA (eds) Viruses and cancer. Cambridge University Press, Cambridge, pp 81–100Google Scholar